Submitted by Anonymous (not verified) on 3 May 2024 - 11:09
Human medicines European public assessment report (EPAR): Tevimbra, tislelizumab, Date of authorisation: 15/09/2023, Revision: 3, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Tevimbra, tislelizumab, Date of authorisation: 15/09/2023, Revision: 3, Status: Authorised